Inogen Inc INGN

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived Nasdaq

Inogen, Inc. is a medical technology business that primarily focuses on respiratory health. We develop, manufacture, and market innovative respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox® product for airway clearance treatment. In addition, we have started distributing the Inogen Voxi® 5 stationary oxygen concentrator as well as the Aurora® continuous positive airway pressure, or CPAP, masks in the United States. Our proprietary Inogen One® and Inogen Rove® POC systems concentrate the air around the patient to offer a source of supplemental oxygen 24 hours a day, seven days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. While often used together with stationary oxygen concentrators and oxygen compressed gas tanks, our POCs are designed to reduce the patient's reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. Our Simeox product is a technology-enabled mucus management device predominantly aimed at serving patients requiring airway clearance, such as those with bronchiectasis – a condition characterized by damaged and widened bronchi that can occur in patients with cystic fibrosis, chronic obstructive pulmonary disease, or COPD, or other chronic respiratory diseases. The Voxi 5 stationary oxygen concentrator is used to provide continuous, long-term oxygen therapy to patients who need supplemental oxygen at home or in clinical settings. The Aurora CPAP masks are used to deliver CPAP therapy through a separate device primarily for treating obstructive sleep apnea, or OSA.

Last close 5.42 2026-09-04
Market cap $143.8M 2026-06-30 share count
52-week range 5.29 - 9.13

Valuation FY2025 figures against the last close

P/S0.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.86

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $295.3M$278.8M$251.6M$320.5M$311.7M$280.2M$340.5M$336.0M$225.5M$168.2M
Cost of revenue $194.4M$181.0M$189.0M$223.7M$181.5M$170.3M$190.1M$179.5M$128.2M$105.5M
Gross profit $154.3M$154.7M$126.7M$153.5M$176.5M$138.2M$171.9M$178.6M$121.2M$97.3M
R&D $19.4M$21.6M$20.8M$21.9M$16.6M$14.1M$9.4M$7.0M$5.3M$5.1M
SG&A $67.4M$72.6M$75.3M$43.9M$37.9M$38.6M$37.1M$38.0M$37.6M$31.8M
Total operating expenses $184.5M$197.3M$236.1M$238.8M$167.2M$150.2M$152.1M$140.7M$93.6M$74.4M
Operating income -$30.2M-$42.5M-$109.4M-$85.2M$9.2M-$12.0M$19.8M$37.9M$27.6M$22.9M
Interest expense —————————$6.0K
Pre-tax income -$23.4M-$36.5M-$102.3M-$83.3M$8.7M-$5.3M$24.3M$40.5M$29.7M$22.7M
Income tax $632.0K$588.0K$105.0K$504.0K$15.0M$549.0K$3.3M$11.4M$8.7M$2.2M
Net income $22.7M$35.9M$102.4M$83.8M$6.3M-$5.8M$20.9M$51.8M$21.0M$20.5M
EPS, basic -0.86-1.52-4.42-3.67-0.28-0.270.962.441.021.02
EPS, diluted -0.86-1.52-4.42-3.67-0.28-0.270.942.300.960.97
Shares, diluted (wtd. avg.) 26.6M23.7M23.2M22.9M22.5M22.0M22.2M22.5M21.9M21.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $103.7M$113.8M$125.5M$187.0M$235.5M$212.0M$198.0M$196.6M$143.0M$92.9M
Short-term investments $15.8M$0$3.0M—$10.0M$19.3M$11.1M$43.7M$31.0M$21.0M
Receivables $38.9M$29.6M$42.2M$62.7M$24.5M$29.7M$34.3M$37.0M$31.4M$30.8M
Inventory $26.0M$24.8M$21.8M$34.1M$31.9M$24.8M$35.7M$27.1M$18.8M$14.3M
Total current assets $198.3M$185.5M$207.1M$304.6M$329.2M$305.7M$292.2M$314.6M$228.5M$161.5M
Property, plant and equipment $36.4M$44.4M$50.3M$43.3M$38.9M$28.2M$19.4M$22.3M$20.1M$25.2M
Goodwill $10.7M$9.5M$10.1M$32.9M$33.0M$33.2M$33.0M$2.3M$2.4M—
Other intangibles $30.8M$30.5M$34.6M$177.0K$60.1M$68.8M$77.5M$3.8M$4.7M$241.0K
Total assets $298.6M$296.2M$326.2M$405.0M$489.5M$461.9M$447.3M$375.9M$275.1M$214.0M
Accounts payable $20.3M$16.6M$13.5M$18.2M$10.3M$12.5M$16.4M$13.7M$9.5M$5.7M
Total current liabilities $63.5M$76.7M$72.5M$65.3M$61.5M$56.7M$50.2M$46.6M$33.9M$22.8M
Total liabilities $106.4M$122.3M$121.4M$107.6M$119.3M$112.2M$102.7M$65.5M$48.0M$32.0M
Retained earnings -$175.6M-$152.8M-$116.9M-$14.5M$69.3M$75.6M$81.4M$60.5M$8.6M-$12.4M
Total equity $192.2M$173.9M$204.8M$297.4M$370.2M$349.6M$344.6M$310.4M$227.0M$182.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$11.2M$5.9M-$3.2M-$37.5M$23.6M$37.0M$40.6M$60.0M$60.5M$31.0M
Depreciation and amortisation $20.7M$21.0M$18.2M$23.5M$21.6M$18.6M$13.8M$11.3M$12.3M$13.6M
Stock-based compensation $8.0M$7.4M$7.4M$12.3M$10.9M$8.2M$9.1M$12.8M$9.6M$7.3M
Capital expenditure $2.5M$3.4M$5.2M$3.3M$5.5M$4.4M$3.1M$8.0M$2.9M$1.7M
Investing cash flow -$26.2M-$14.0M-$59.3M-$10.9M-$14.6M-$25.6M-$44.1M-$25.0M-$24.4M-$11.9M
Financing cash flow $24.2M$265.0K$960.0K$380.0K$15.0M$2.1M$4.9M$18.3M$14.0M$7.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001294133-26-000009.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Capital expenditure
  • Receivables
  • Total current liabilities
  • Inventory
Capital expenditure, Receivables, Total current liabilities, Inventory by fiscal year, in US dollars The same figures are in the table below this chart. 0 20M 40M 60M 80M Capital expenditure, FY2016: 1.7M Receivables, FY2016: 30.8M Total current liabilities, FY2016: 22.8M Inventory, FY2016: 14.3M Capital expenditure, FY2017: 2.9M Receivables, FY2017: 31.4M Total current liabilities, FY2017: 33.9M Inventory, FY2017: 18.8M Capital expenditure, FY2018: 8M Receivables, FY2018: 37M Total current liabilities, FY2018: 46.6M Inventory, FY2018: 27.1M Capital expenditure, FY2019: 3.1M Receivables, FY2019: 34.3M Total current liabilities, FY2019: 50.2M Inventory, FY2019: 35.7M Capital expenditure, FY2020: 4.4M Receivables, FY2020: 29.7M Total current liabilities, FY2020: 56.7M Inventory, FY2020: 24.8M Capital expenditure, FY2021: 5.5M Receivables, FY2021: 24.5M Total current liabilities, FY2021: 61.5M Inventory, FY2021: 31.9M Capital expenditure, FY2022: 3.3M Receivables, FY2022: 62.7M Total current liabilities, FY2022: 65.3M Inventory, FY2022: 34.1M Capital expenditure, FY2023: 5.2M Receivables, FY2023: 42.2M Total current liabilities, FY2023: 72.5M Inventory, FY2023: 21.8M Capital expenditure, FY2024: 3.4M Receivables, FY2024: 29.6M Total current liabilities, FY2024: 76.7M Inventory, FY2024: 24.8M Capital expenditure, FY2025: 2.5M Receivables, FY2025: 38.9M Total current liabilities, FY2025: 63.5M Inventory, FY2025: 26M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Capital expenditure $1.7M $2.9M $8.0M $3.1M $4.4M $5.5M $3.3M $5.2M $3.4M $2.5M
Receivables $30.8M $31.4M $37.0M $34.3M $29.7M $24.5M $62.7M $42.2M $29.6M $38.9M
Total current liabilities $22.8M $33.9M $46.6M $50.2M $56.7M $61.5M $65.3M $72.5M $76.7M $63.5M
Inventory $14.3M $18.8M $27.1M $35.7M $24.8M $31.9M $34.1M $21.8M $24.8M $26.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $129.55B 46.6x 20.5%
EW Edwards Lifesciences Corp $51.82B 49.1x 11.5%
STE STERIS plc $21.90B 28.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.71B 27.6x 7.2%
ALGN ALIGN TECHNOLOGY INC $11.27B 28.1x 0.9%
MSA MSA Safety Inc $7.28B 26.6x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $2.21B — 27.1%
CDRE Cadre Holdings, Inc. $1.27B 29.2x 7.5%